Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -133K | -1M | -1M | -650K | -1M |
| Operating Income | -86M | -85M | -80M | -77M | -58M |
| EBITDA | -86M | -74M | -68M | -73M | -57M |
| Net Income | -78M | -59M | -69M | -73M | -58M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.13
+2.73% today
1Y Change
-0.93%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PMV Pharmaceuticals, Inc. (PMVP) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.13 and down 0.9% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -30.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -30.0%, free cash flow -41.7% with operating margin 0.0% and ROIC -79.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PMVP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMVP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMVP Max Drawdown
-41.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMVP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$57.8M
+21.1% YoY
Free Cash Flow
-$47.9M
+33.2% YoY
Revenue Growth
+0.0%
EPS Growth
-30.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -133K | -1M | -1M | -650K | -1M |
| Operating Income | -86M | -85M | -80M | -77M | -58M |
| EBITDA | -86M | -74M | -68M | -73M | -57M |
| Net Income | -78M | -59M | -69M | -73M | -58M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38M | 41M | 38M | 108M | 172M |
| Total Assets | 117M | 191M | 252M | 270M | 332M |
| Total Liabilities | 12M | 15M | 26M | 24M | 23M |
| Shareholder Equity | 105M | 176M | 226M | 246M | 309M |
| Total Debt | 838K | 1M | 13M | 14M | 11M |
| Net Debt | -37M | -40M | -24M | -94M | -161M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
47M
+27.0% YoY
Capital Expenditures
1M
+83.1% YoY
Free Cash Flow
48M
+33.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-59.1%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.